DASON COVID-19 Weekly Treatment Literature Update 6/19/2020
Prepared by: Angelina Davis, PharmD, MS, April Dyer, PharmD, MBA, MSCR, Elizabeth Dodds Ashley, PharmD, MHS, Melissa Johnson, PharmD, MHS, S. Shaefer Spires, MD, Travis Jones, PharmD

The following summarizes key literature pertaining to treatment of COVID-19 during the past week. *Note: some of the data discussed below is in pre-print form that has not yet been peer-reviewed. We have noted some discrepancies in some of this data, and final printed versions may ultimately differ from what is shown here. We will update as soon as possible; caution is advised when interpreting this literature.

New Literature This Week
Earlier this week, a press release was issued describing results of the RECoVERY trial. This is a multi-arm study being conducted in the UK. The Steering Committee has decided to halt the dexamethasone arm of the trial based on favorable results. The release states that ventilated patients receiving dexamethasone had a 30% lower mortality than standard of care. A similar, but smaller effect (20% lower mortality) was seen in patients on supplemental oxygen. A drug with a proven mortality benefit for patients with COVID-19 is desperately needed and these results are promising. However, without access to the peer reviewed clinical trial data, it is difficult to make firm conclusions regarding the role of dexamathasone in care of COVID-19 patients. We will continue to provide updates when the data become available.


Treatment Summary Tables
The remdesivir summary table with the information of published studies to date can be found at this link: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-remdesivir-covid-19

The hydroxychloroquine summary table is available at this link: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-hydroxychloroquine-and-chloroquine-covid-19

The NEW tocilizumab summary table with the information of published studies to date can be found at this link: https://dason.medicine.duke.edu/summary-recent-clinical-data-use-tocilizumab-covid-19